AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$57.02 USD
+0.73 (1.30%)
Updated Jul 17, 2024 04:00 PM ET
After-Market: $57.03 +0.01 (0.02%) 6:26 PM ET
5-Strong Sell of 5 5
A Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.02 USD
+0.73 (1.30%)
Updated Jul 17, 2024 04:00 PM ET
After-Market: $57.03 +0.01 (0.02%) 6:26 PM ET
5-Strong Sell of 5 5
A Value C Growth B Momentum B VGM
Zacks News
Masimo's (MASI) SpHb During Elective CS Favored by New Study
by Zacks Equity Research
Masimo's (MASI) SpHb is likely to indicate clinically acceptable accuracy of Hb measurement even at low Hb levels in patients undergoing CS with antepartum hemorrhage.
Here's Why You Should Retain PacBio (PACB) Stock for Now
by Zacks Equity Research
PacBio's (PACB) strength in its Sequel system raises optimism about the stock.
Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens' (WBA) strategic executions on both the United States and the international front are likely to have contributed to the Q1 2023 top line.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.
Are Medical Stocks Lagging AMN Healthcare Services (AMN) This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
Molina's (MOH) California Medicaid Revenues to Double in 2024
by Zacks Equity Research
Molina Healthcare (MOH) expects combined revenues from California, Nebraska, and Iowa in 2024 to reach $4.2 billion.
Why Hold Strategy is Apt for Centene (CNC) Stock Right Now
by Zacks Equity Research
Centene's (CNC) health benefits ratio is expected to improve in the coming days, signaling better operating efficiency.
AMN or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed at $103 in the latest trading session, marking a +0.2% move from the prior day.
AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $103.46, marking a +0.46% move from the previous day.
AMN Healthcare (AMN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AMN Healthcare (AMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AmerisourceBergen (ABC) to Repurchase Common Stock Worth $200M
by Zacks Equity Research
AmerisourceBergen (ABC) announces a share repurchase worth $200 million in concurrence with the sale of its shares by one of its shareholders, Walgreens Boots Alliance, under Rule 144.
LabCorp (LH) Gains on Innovation Amid Currency Headwinds
by Zacks Equity Research
LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to help match patients with critical and potentially life-changing treatments for cancer and other diseases.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH), led by strength in its Drug Development business.
HealthEquity (HQY) Stock Falls 1.6% Despite Q3 Earnings Beat
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust performances in all its segments in the third quarter of fiscal 2023.
Quest Diagnostics' (DGX) New Deal to Extend Laboratory Access
by Zacks Equity Research
Quest Diagnostics' (DGX) new collaboration with Northern Light Health will enhance access to diagnostics services in Maine.
Cooper Companies (COO) Q4 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal fourth-quarter revenues reflect a solid segmental performance.
LabCorp's (LH) New APH Lab to Expand Global Capabilities
by Zacks Equity Research
LabCorp's (LH) new laboratory is likely to advance clinical trials across therapeutic areas like oncology, hemato-oncology and liver diseases.
Masimo (MASI) W1 Watch With Hi to Improve Patient Outcome
by Zacks Equity Research
Masimo's (MASI) full-market release of the Hi for the Masimo W1 watch is likely to significantly improve RPM.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Zimmer Biomet (ZBH) Procedure Volume Gain Aids Amid FX Hurdles
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to face significant challenges in terms of unfavorable foreign exchange, supply, inflation and staffing shortage.
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Acadia (ACHC) Reveals its Long-Term Goals: What You Should Know
by Zacks Equity Research
From 2022 to 2028, Acadia Healthcare (ACHC) expects to see a 9-11% CAGR in revenues.
3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.